The U.S. Food and Drug Administration (FDA) approved on June 25th the cannabis-derived drug Epidiolex for treatment of seizures that are associated with two forms of epilepsy.
Epidiolex is a cannabidiol (CBD) containing drug that does not contain any psychoactive ingredients like tetrahydrocannabinol (THC) and is taken in an oral solution form.
The two forms of epilepsy that Epidiolex is now FDA approved to treat is Lennox-Gastaut syndrome and Dravet syndrome. The drug is approved to treat patients with these syndromes from the minimum age of two years old and older.
Epidiolex is the first FDA-approved drug that uses organic matter that is purified from the cannabis plant itself. Other medications and treatments use a synthetic creation that is synthesized in a laboratory.